Gyroscope Therapeutics, a British gene therapy company with a presence in Philadelphia, entered into a two-year sponsored research agreement with the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop novel gene therapies for serious eye diseases that can lead to permanent vision loss. CAROT is led by Jean Bennett, PhD, whose lab invented and developed the approved gene therapy product marketed by Spark Therapeutics under the brand name Luxturna™ for the treatment of Leber Congenital Amaurosis, an inherited retinal disorder. Under the research collaboration between Penn’s CAROT and Gyroscope, the two parties will work together to explore specific gene therapy candidates for the treatment of glaucoma, optic neuritis and retinitis pigmentosa.
